FFDCA

United States Commercial Greenhouse Market Report 2023-2028: From Farm to Table - Meeting the Demand for Fresh Produce

Retrieved on: 
Monday, February 5, 2024
Atlas, Appharvest, Vegetable, Flower, Food quality, Supermarket, Appetite, FQPA, ESA, Water, Hydroponics, Compound, Sustainable agriculture, FFDCA, Endangered species, Agriculture

DUBLIN, Feb. 5, 2024 /PRNewswire/ -- The "U.S. Commercial Greenhouse Market Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 5, 2024 /PRNewswire/ -- The "U.S. Commercial Greenhouse Market Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The latest market intelligence report on the U.S. commercial greenhouse industry underlines a substantial growth trajectory for the sector, with expectations to reach an impressive US$837.885 million by 2028.
  • As demand for year-round produce continues to climb, commercial greenhouses in the United States are experiencing an upswing, providing necessary supply chains for supermarkets and consumers with an appetite for fresh, organic, and sustainably sourced fruits and vegetables.
  • Local Food Revolution: Local and hyper-local food trends have leveraged the commercial greenhouse market by meeting consumer preferences for local produce availability around the calendar year.

Center for Contemporary Sciences (CCS) Applauds Congress for Passing the FDA Modernization Act that Will Save Millions of Lives.

Retrieved on: 
Friday, December 23, 2022
Human, Death, Harvard University, FFDCA, Patient, Federal Food, Drug, and Cosmetic Act, Entrepreneurship, Drug discovery, Wyss Institute for Biologically Inspired Engineering, Liver, Health, Drug development, Biology, FDA, Safety, Animal, CCS, MPH, Multimedia, Congress, Wyss Institute, Pharmaceutical industry, Bethanie Mattek-Sands, MD

WASHINGTON, Dec. 23, 2022 /PRNewswire/ -- In a significant step for the advancement of human health, Congress passed the FDA Modernization Act as part of the FY2023 Omnibus Appropriations Bill.

Key Points: 
  • WASHINGTON, Dec. 23, 2022 /PRNewswire/ -- In a significant step for the advancement of human health, Congress passed the FDA Modernization Act as part of the FY2023 Omnibus Appropriations Bill.
  • In Section 3209 titled "Animal Testing Alternatives," the bill amends the regulatory guidance at the FDA that requires animal testing for drugs and biosimilars.
  • A recent, comprehensive study shows the superiority of Liver-Chips in predicting drug liver toxicity in humans, as compared to animal testing.
  • Center for Contemporary Sciences (CCS) is pioneering a paradigm shift towards innovative, evidence-based research methods that are based on human biology.

New Scientific Publication Describes Twelve Reasons Why Organ-Chips are Better than Animal Testing

Retrieved on: 
Friday, December 16, 2022
Hepatotoxicity, Drug development, Federal Food, Drug, and Cosmetic Act, MPA, Pharmaceutical innovations, Doctor of Philosophy, Patient, Disease, Entrepreneurship, Science, Animal, Toxicity, Biology, Liver, Medicine, MPH, CCS, Human, Death, Multimedia, Safety, Emulate, Health, FFDCA, Medical device, Pharmaceutical industry, MD

As such, a growing number of stakeholders worldwide are demanding human relevancy across scientific research, including preclinical studies and drug development.

Key Points: 
  • As such, a growing number of stakeholders worldwide are demanding human relevancy across scientific research, including preclinical studies and drug development.
  • Specifically, the Emulate human Liver-Chips correctly identified 87% of drugs that caused serious liver toxicity and deaths in patients despite passing through animal testing.
  • Advanced testing methods based on human biology will revolutionize the way we approach medicine and health and lead to individualized medicine."
  • We champion technologies that are better for humans and that replace animal testing.

Center for Contemporary Sciences (CCS) Applauds the Senate for Passing the FDA Modernization Act 2.0, Recognizing the Great Bipartisan Efforts of Senators Rand Paul and Cory Booker.

Retrieved on: 
Thursday, September 29, 2022
Federal Food, Drug, and Cosmetic Act, FFDCA, Human, FDA, Food, Center, Legislation, Emulate, Food and Drug Administration Modernization Act of 1997, News, Jane Goodall, HELP, United States Senate Committee on Health, Education, Labor and Pensions, Senate, CCS, Biology, United States House Energy Subcommittee on Health, House, Drug development, Negotiation, Jane Goodall Institute, Commerce, United States Senate, Conference, Actin, Multimedia, Education, Labour, View, Pharmaceutical industry, Pension, Health

In swift reaction, Senators Booker and Paul reintroduced the FDA Modernization Act 2.0, S.5002 separately for consideration by the Senate today.

Key Points: 
  • In swift reaction, Senators Booker and Paul reintroduced the FDA Modernization Act 2.0, S.5002 separately for consideration by the Senate today.
  • In doing so, the FDA Modernization Act introduces much-needed improvement to the process of drug development.
  • A growing number of stakeholders have voiced their support for the FDA Modernization Act.
  • Center for Contemporary Sciences (CCS) is pioneering a paradigm shift towards innovative, evidence-based research methods that are based on human biology.

Senate Committee Fails to Include the FDA Modernization Act of 2021 in a Key Legislative Package, which the Center for Contemporary Sciences Calls a "Step Against Medical Progress."

Retrieved on: 
Wednesday, September 28, 2022
Federal Food, Drug, and Cosmetic Act, FFDCA, Human, Hiccup, FDA, Food, Center, Legislation, Emulate, Food and Drug Administration Modernization Act of 1997, News, Jane Goodall, HELP, Senate, CCS, Representative, Biology, House, Drug development, Congress, Negotiation, Jane Goodall Institute, United States Senate, Conference, Education, Louisiana House of Representatives, Labour, United States House of Representatives, Medical device, Pharmaceutical industry, Pension, Health

In doing so, the FDA Modernization Act introduces much-needed improvement to the process of drug development.

Key Points: 
  • In doing so, the FDA Modernization Act introduces much-needed improvement to the process of drug development.
  • Such a change is expected to speed up the discovery process and lower the cost of life-saving medicine.
  • A growing number of stakeholders have voiced their support for the FDA Modernization Act of 2021 (H.R.2565 / S.2952).
  • Center for Contemporary Sciences (CCS) is pioneering a paradigm shift towards innovative, evidence-based research methods that are based on human biology.

Dr. Jane Goodall and Vivodyne Issue Open Letter to Congressional Leaders to Include FDA Modernization Act as a Rider in the Food and Drug Amendments Act of 2022

Retrieved on: 
Thursday, September 8, 2022
Research, Pharmaceutical, White House, Federal Government, Animal Welfare, Healthcare Reform, Science, Veterinary, Biotechnology, FDA, Congressional News, Views, Health, Public Policy, Government, Jane Goodall, Human, Safety, Cancer, Research, FFDCA, Vaccine, Food and Drug Administration Modernization Act of 1997, Disease, Tissue, Mouse, Letter, Stem cell, Food, Intelligence, MPS, Education, Animal, New, Jane Goodall Institute, FDA, Therapy, Founder, Risk, European Menopause and Andropause Society, Congress, DBE, Health, Patient, Pharmaceutical industry, Medical device

We cannot continue to vainly expect caged animals to accurately predict human drug responses.

Key Points: 
  • We cannot continue to vainly expect caged animals to accurately predict human drug responses.
  • Mandating that such promising drugs are tested on animals where they are guaranteed to fail, will only inhibit their further development.
  • Importantly, these modern approaches do not rely on the use of embryonic stem cells or other materials that raise ethical concerns.
  • We thank you and appreciate your support for the FDA Modernization Act by including it in the FDA User Fee package.

The Worldwide Cosmetic Preservatives Industry is Projected to Reach $562 Million by 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 26, 2022
Cosmetics, Retail, Chemicals, Plastics, Manufacturing, People, Federal Food, Drug, and Cosmetic Act, Male, Cosmetics, Skin, Environment, Awareness, Food, Female, Woman, Disclosure, Food and Drug Administration, Central Drugs Standard Control Organisation, Bureau, CDSCO, Bureau of Labor Statistics, USD, Paraben, Hair, CAGR, FDA, Acne, Man, Bureau of Indian Standards, Drug, Growth, FFDCA, Population, Asia-Pacific

The cosmetic preservatives market is estimated to be USD 410 million in 2022 and is projected to reach USD 562 million by 2027, at a CAGR of 6.5% between 2022 and 2027.

Key Points: 
  • The cosmetic preservatives market is estimated to be USD 410 million in 2022 and is projected to reach USD 562 million by 2027, at a CAGR of 6.5% between 2022 and 2027.
  • Therefore, financial independence is expected to boost the consumption of cosmetics and skin care products, thereby increasing the consumption of cosmetic preservatives.
  • The Federal Food, Drug, and Cosmetic Act (FFDCA) passed by the FDA regulates the usage of cosmetic preservatives in cosmetic products in the US.
  • Though there is high demand for natural and organic cosmetic preservatives, the high costs of preservatives pose a challenge for cosmetic manufacturers.

The Center for Contemporary Sciences Applauds House members for hearing on FDA Modernization Act of 2021.

Retrieved on: 
Thursday, March 24, 2022
Hearing, CCS, Senate, Drug development, Bethanie Mattek-Sands, Human, Federal Food, Drug, and Cosmetic Act, Multimedia, Legislation, Patient, University of North Carolina at Pembroke, Wyss Institute for Biologically Inspired Engineering, Doctor of Philosophy, United States House Energy Subcommittee on Health, Medicine, House, Harvard University, MD, Assam Global Investors' Summit, FFDCA, Biology, Food and Drug Administration Modernization Act of 1997, FDA, Wyss Institute, University, Chapel Hill, Medical device, Pharmaceutical industry

The FDA Modernization Act of 2021 is a key legislation designed to modernize drug development.

Key Points: 
  • The FDA Modernization Act of 2021 is a key legislation designed to modernize drug development.
  • But major developments have been made since 1938 in creating effective test methods that are based on human biology.
  • The FDA Modernization Act of 2021 amends the FFDCA by broadening options for drug development to include modern, innovative, human-relevant test methods.
  • "This hearing is a key step in the right direction," said Dr. Zaher Nahle, Chief Science Officer at CCS.

Global Pet Supplements Market (2021 to 2027) - Featuring Dechra Pharmaceuticals, Nestle and Zoetis Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Retail, Health, Consumer, Specialty, Pets, Veterinary, People, Mineral, FFDCA, Anxiety, Federal Food, Drug, and Cosmetic Act, Protein, FDA Food Safety Modernization Act, Immunity, PETS, E-commerce, Growth, Food safety, Vitamin, COVID-19, Dog, Adoption, Vaccine, FSMA, Taste, Patient, Hygiene, American Pet Products Association, Longevity, Maintenance, Nutrient, Health, Certification, APPA, Sterilization, Pet, Animal, Bottled water, Pet

The rising expenditure on pet care around the world and the high increment in the adoption of pets are fueling the market growth.

Key Points: 
  • The rising expenditure on pet care around the world and the high increment in the adoption of pets are fueling the market growth.
  • Pet owners are willingly spending a massive amount of money to maintain the health of their pets, leading to higher pet health spending.
  • As per the American Pet Products Association, overall household pet adoption in the US grew significantly in 2016.
  • The players working in the global pet supplement market are witnessing massive growth opportunities due to the booming eCommerce websites.

The Center for Contemporary Sciences (CCS) Cheers Bipartisan Introduction of the FDA Modernization Act of 2021 to Innovate Drug Development and Replace Animal Testing Requirements

Retrieved on: 
Thursday, October 7, 2021
Biology, Doctor of Philosophy, Federal Food, Drug, and Cosmetic Act, Wyss Institute, CCS, Multimedia, Drug development, Safety, Human, FDA, Food and Drug Administration Modernization Act of 1997, FFDCA, Hope, Harvard University, European Parliament, Science, MPA, MPH, Medical device, Pharmaceutical industry

The existing drug development paradigm, established by statute in 1938 under the Federal Food, Drug, and Cosmetics Act (FFDCA), requires animal tests to be conducted in all new drug applications.

Key Points: 
  • The existing drug development paradigm, established by statute in 1938 under the Federal Food, Drug, and Cosmetics Act (FFDCA), requires animal tests to be conducted in all new drug applications.
  • The FDA Modernization Act of 2021 amends the FFDCA by broadening options for drug development to include modern, innovative, human-relevant test methods.
  • "The European Parliament recently voted to phase out animal testing and replace it with human-relevant methods.
  • We champion technologies that are better for humans and that replace animal testing.